CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

ABSTRACT: Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially acute lymphoblastic leukemia (ALL) ¹ . Although a majority of patients will achieve a complete response following a single infusion of CD19-targeted CAR-modified T cells (CD19 CAR T cells)^2-4, the broad applicability of this treatment is hampered by severe cytokine release syndrome (CRS), which is characterized by fever, hypotension and respiratory insufficiency associated with elevated serum cytokines, including interleukin-6 (IL-6)^2,5. CRS usually occurs within days of T cell infusion at the peak of CAR T cell expansion. In ALL, it is most frequent and more severe in patients with high tumor burden^2-4. CRS may respond

SUBMITTER: Giavridis T 

PROVIDER: S-EPMC6410714 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature